Beijing Bencao Ruisheng Pharmaceutical Technology Hong Kong

Beijing Bencao Ruisheng Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with an additional corporate presence in Hong Kong. The company is dedicated to the discovery and development of innovative small molecule therapeutics, with a primary focus on oncology and metabolic disorders. Its lead clinical candidate, BR-101, is a potent and selective inhibitor of the fibroblast growth factor receptor (FGFR) family, currently being evaluated in Phase 1/2 clinical trials for patients with advanced solid tumors. Bencao Ruisheng aims to address significant unmet medical needs by leveraging its internal research capabilities to develop high-quality targeted therapies. The company's pipeline also includes several early-stage programs targeting various oncogenic pathways.